Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

Abstract Introduction This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarth...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Gerd R. Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F. Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, Lianne S. Gensler
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2024-04-01
Edice:	Rheumatology and Therapy
Témata:	Adalimumab Ankylosing spondylitis JAK inhibitor Non-radiographic axial spondyloarthritis Psoriatic arthritis Safety
On-line přístup:	https://doi.org/10.1007/s40744-024-00671-4
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!